폐이식 환자에서 tacrolimus와 itraconazole 혹은 voriconazole 병용 시 tacrolimus의 혈중 농도 변화에 미치는 영향
Effect of Voriconazole or Itraconazole on the Plasma Concentrations of Tacrolimus in Lung Transplant Recipients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: This study was performed to compare the changes in the blood concentrations of tacrolimus when either itraconazole or voriconazole is together with tacrolimus to prevent or treat invasive aspergillus pneumonia (IAP) in patients with lung transplants. Therefore we can compare the degree of drug-drug interactions between tacrolimus and itraconazole against tacrolimus and voriconazole. Methods: Patients who were admitted and had lung transplants in a territory referral hospital from September 2012 to May 2015 were analyzed retrospectively. The effects of itraconazole and voriconazole on the plasma concentrations of tacrolimus were analyzed. Results: Mean tacrolimus concentrations was 10.49±2.35 ng/mL vs. 10.95±2.98 ng/mL (p=0.722), and mean concentration of tacrolimus over the dose of tacrolimus per day was 8.510±5.890 (ng/mL)/(mg/d) vs. 15.45±28.47 (ng/mL)/(mg/d) (p=0.947) in itraconazole vs. voriconazole group each. The ratio of the number of the results out of target tacrolimus concentrations to the total number of tacrolimus concentration results was 18.0±13.3% vs. 24.4±18.5% (p=0.185). Conclusion: There were no significant differences between itraconzaole and voriconazole to have influences on mean concentrations of tacrolimus over tacrolimus dose per weight per day. However voriconazole tended to raise tacrolimus plasma concentrations more than itraconazole. Safer and more effective drug management to prevent and treat fungal infections should be done by therapeutic drug monitoring not only of tacrolimus but of itraconazole and voriconazole in lung transplant patients.
Abstract
Objective: This study was performed to compare the changes in the blood concentrations of tacrolimus when either itraconazole or voriconazole is together with tacrolimus to prevent or treat invasive aspergillus pneumonia (IAP) in patients with lung transplants. Therefore we can compare the degree of drug-drug interactions between tacrolimus and itraconazole against tacrolimus and voriconazole. Methods: Patients who were admitted and had lung transplants in a territory referral hospital from September 2012 to May 2015 were analyzed retrospectively. The effects of itraconazole and voriconazole on the plasma concentrations of tacrolimus were analyzed. Results: Mean tacrolimus concentrations was 10.49±2.35 ng/mL vs. 10.95±2.98 ng/mL (p=0.722), and mean concentration of tacrolimus over the dose of tacrolimus per day was 8.510±5.890 (ng/mL)/(mg/d) vs. 15.45±28.47 (ng/mL)/(mg/d) (p=0.947) in itraconazole vs. voriconazole group each. The ratio of the number of the results out of target tacrolimus concentrations to the total number of tacrolimus concentration results was 18.0±13.3% vs. 24.4±18.5% (p=0.185). Conclusion: There were no significant differences between itraconzaole and voriconazole to have influences on mean concentrations of tacrolimus over tacrolimus dose per weight per day. However voriconazole tended to raise tacrolimus plasma concentrations more than itraconazole. Safer and more effective drug management to prevent and treat fungal infections should be done by therapeutic drug monitoring not only of tacrolimus but of itraconazole and voriconazole in lung transplant patients.
참고문헌 (28)
- Haam SJ, "An overview of lung transplantation in Korea.", Transplant Proc, 40(8), pp.2620~2622 (2008)
- KONOS Annual Report 2014, "Ministry of Health & Welfare", ~ (2014)
- Synder LD, "Immune mechanisms of lung allograft rejection", Semin Respir Crit Care Med, 27(5), pp.534~543 (2006)
- Morgan J, "Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation:interim results of a prospective multicenter surveillance program", Med Mycol, 43(Suppl1), pp.S49~58 (2005)
- Lin SJ, "Aspergillosis case-fatality rate: systematic review of the literature", Clin Infect Dis, 32(3), pp.358~366 (2001)
- Husain S, "Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients", Am J Transplant, 4(5), pp.796~802 (2004)
- Shitrit D, "Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction", J Heart Lung Transplant, 24(12), pp.2148~2152 (2005)
- Walsh TJ, "Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America", Clin Infect Dis, 46(3), pp.327~360 (2008)
- Segal BH, "Aspergillosis", N Engl J Med, 360(18), pp.1870~1884 (2009)
- Herbrecht R, "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N Engl J Med, 347(6), pp.408~415 (2002)
- He SY, "Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national survey", Transpl Infect Dis, 17(1), pp.14~20 (2015)
- Zonios DI, "Update on azole antifungals", Semin Respir Crit Care Med, 29(2), pp.198~210 (2008)
- Snell GI, "Immunosuppression and allograft rejection following lung transplantation: evidence to date", Drugs, 73(16), pp.1793~1813 (2013)
- Chiang CY, "Tacrolimus Level Variability Is a Novel Measure Associated with Increased Acute Rejection in Lung Transplant (LTx) Recipients", J Heart Lung Transplant, 32(4), pp.S170~
- Pollock-Barziv SM, "Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children", Pediatr Transplant, 14(8), pp.968~975 (2010)
- van Gelder T, "Drug interactions with tacrolimus", Drug Saf, 25(10), pp.707~712 (2002)
- Billaud EM, "Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients", Med Mycol, 48(Suppl1), pp.S52~S59 (2010)
- Singh N, "Invasive Aspergillosis in Solid Organ Transplant Recipients", Am J Transplant, 9, pp.S180~S191 (2009)
- J.M. Morton, "Trough levels are inadequate for monitoring tacrolimus pharmacokinetics in lung transplantation", J Heart Lung Transplant, 21(1), pp.144~ (2002)
- "Prescribing information. Vfend (voriconazole)"[URL]
- Dodds-Ashley E, "Management of drug and food interactions with azole antifungal agents in transplant recipients", Pharmacotherapy, 30(8), pp.842~854 (2010)
- Capone D, "Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient", J Clin Pharm Ther, 35(1), pp.121~124 (2010)
- Venkataramanan R, "Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes", Antimicrob Agents Chemother, 46(9), pp.3091~3093 (2002)
- Mori T, "Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation", Int J Hematol, 95(5), pp.564~569 (2012)
- Saad AH, "Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants", Pharmacotherapy, 26(12), pp.1730~1744 (2006)
- Antiviral drugs advisory committee, "F D A. Briefing Document for Voriconazole(Oral and Intravenous Formulations)", US Food and Drug Administration, ~ (2001)
- Association Study Between Drugmetabolizing Enzyme Genotype and Pharmacokinetics, "Ministry of Food and Drug Safety", ~ (2010)
- "Prescribing information of Prograf (tacrolimus)"[URL]